Deputy Director of the General Office of the Clinical Research Institute, Chief Physician of the Department of Nuclear Medicine, and Professor.
Affiliated HospitalPeking Union Medical College Hospital, Chinese Academy of Medical Sciences
→
Research areas: Clinical diagnostic applications of PET/CT and related basic clinical research; radiopharmaceutical development and clinical translation.
Cutting-edge technologies: Leading the development of the innovative EB-PSMA-17 drug, extending the drug's half-life and improving tumor uptake and retention through Evans blue (EB) structural modification. Leading the completion of a nationwide multicenter clinical trial (11 tertiary hospitals, 409 clinical trial participants) of the "world's first" radioactive drug Technetium-Tc Pexiretide Glycopeptide Injection. Conducting clinical research on Ga-FAPI-RGD PET/CT diagnosis and 177Lu-FAPI-RGD radioligand therapy for metastatic tumors.
Areas of expertise: 177Lu-PSMA radioligand therapy for prostate cancer, PET/CT tumor diagnosis, and clinical evaluation of new radiopharmaceuticals.
Academic Highlights and Core Values: Deputy Director of the General Office of the Clinical Research Institute, Chief Physician of the Department of Nuclear Medicine, and Professor. He spearheaded a groundbreaking original breakthrough in my country's radiopharmaceutical field, marking a significant step forward for China in the international forefront of innovative radiopharmaceutical research and development.